Spots Global Cancer Trial Database for A Single Arm Study of Ipilimumab Monotherapy in Patients With Previously Treated Unresectable Stage III or IV Melanoma
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A Single Arm Study of Ipilimumab Monotherapy in Patients With Previously Treated Unresectable Stage III or IV Melanoma
Official Title: A Multi-Center Single Arm Phase II Study of MDX-010 (BMS-734016) Monotherapy in Patients With Previously Treated Unresectable Stage III or IV Melanoma
Study ID: NCT00289627
Conditions
Interventions
Study Description
Brief Summary: The purpose of this clinical research study is to evaluate the Best Overall Response Rate (BORR), (as per modified WHO criteria) in patients with previously treated melanoma-Stage III (unresectable) or Stage IV melanoma receiving 10 mg/kg of ipilimumab. The safety of this product will also be evaluated.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
, Little Rock, Arkansas, United States
, San Francisco, California, United States
, Santa Monica, California, United States
, Chicago, Illinois, United States
, Park Ridge, Illinois, United States
, Goshen, Indiana, United States
, Hazard, Kentucky, United States
, Alburquerque, New Mexico, United States
, New York, New York, United States
, Portland, Oregon, United States
, Greenville, South Carolina, United States
, Knoxville, Tennessee, United States
, Dallas, Texas, United States
, Charlottesvillle, Virginia, United States
Local Institution, Salzburg, , Austria
Local Institution, Wels, , Austria
Local Institution, Wien, , Austria
Local Institution, Turku, , Finland
Local Institution, Genova, , Italy
Local Institution, Meldola, , Italy
Local Institution, Milano, , Italy
Local Institution, Napoli, , Italy
Local Institution, Padova, , Italy
Local Institution, Siena, , Italy
Local Institution, Torino, , Italy
Local Institution, Oslo, , Norway
Local Institution, Lodz, , Poland
Local Institution, Poznan, , Poland
Local Institution, Wroclaw, , Poland
Local Institution, Barnaul, , Russian Federation
Local Institution, Moscow, , Russian Federation
Local Institution, Murmansk, , Russian Federation
Local Institution, Ryazan, , Russian Federation
Local Institution, Samara, , Russian Federation
Local Institution, St Petersburg, , Russian Federation
Local Institution, St. Petersburg, , Russian Federation
Local Institution, Stavropol, , Russian Federation
Local Institution, Velikiy Novgorod, , Russian Federation
Local Institution, Voronezh, , Russian Federation
Local Institution, Barcelona, , Spain
Local Institution, Madrid, , Spain
Local Institution, Malaga, , Spain
Local Institution, Tenerife, , Spain
Local Institution, Valencia, , Spain
Local Institution, Goteborg, , Sweden
Local Institution, Lund, , Sweden
Local Institution, Stockholm, , Sweden
Local Institution, Uppsala, , Sweden
Local Institution, Cherkassy, , Ukraine
Local Institution, Dnipropetrovsk, , Ukraine
Local Institution, Kiev, , Ukraine
Local Institution, Lvov, , Ukraine
Local Institution, Sumy, , Ukraine
Local Institution, Uzhgorod, , Ukraine
Contact Details
Name: Bristol-Myers Squibb
Affiliation: Bristol-Myers Squibb
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
